Total submissions: 16
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000031219 | SCV000244383 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-08-10 | reviewed by expert panel | curation | IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 5 based on posterior probability = 1 |
Laboratory for Molecular Medicine, |
RCV000219187 | SCV000271207 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2015-11-17 | criteria provided, single submitter | clinical testing | The p.Gly1727Glu variant in BRCA1 has been reported in at least 9 individuals wi th breast cancer, segregated with disease in 2 affected relatives from 1 family (Osorio 2000, Iyevleva 2010, Breast Cancer Information Core (BIC) database), and was absent from large population studies. In vitro functional studies provide s ome evidence that the missense variant may impact protein function (Bouwman 2013 ). However, these types of assays may not accurately represent biological functi on. Computational prediction tools and conservation analysis do not provide stro ng support for or against an impact to the protein. In summary, although additio nal studies are required to fully establish its clinical significance, the p.Gly 1727Glu variant is likely pathogenic. |
Ambry Genetics | RCV000221607 | SCV000277516 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2024-01-29 | criteria provided, single submitter | clinical testing | The p.G1706E variant (also known as c.5117G>A), located in coding exon 16 of the BRCA1 gene, results from a G to A substitution at nucleotide position 5117. The glycine at codon 1706 is replaced by glutamic acid, an amino acid with similar properties. This alteration has been reported in numerous breast and ovarian cancer families and has been described as a Spanish founder mutation that segregates with disease in multiple, affected family members (Osorio A et al. Br J Cancer. 2000 Apr;82(7):1266-70; Diez O et al. Hum Mutat. 2003 Oct;22(4):301-12; Janavicius R. EPMA J. 2010 Sep;1(3):397-412; Iyevleva AG et al. Cancer Lett. 2010 Dec 8;298(2):258-63; Rebbeck TR et al. Hum Mutat, 2018 05;39:593-620; Zeng C et al. Breast Cancer Res Treat, 2020 Jun;181:465-473). Functional assays have also shown this alteration to have a deleterious biological effect (Carvalho MA et al. Cancer Res. 2007 Feb 15;67(4):1494-501; Lee MS et al. Cancer Res. 2010 Jun 15;70(12):4880-90; Bouwman P et al. Cancer Discov. 2013 Oct;3(10):1142-55; Woods NT et al. npg Genomic Medicine 2016: 1:16001; Findlay GM et al. Nature, 2018 10;562:217-222). This alteration has been classified as pathogenic by multifactorial analysis, which integrates the following lines of evidence to produce a quantitative likelihood of pathogenicity: in silico prediction models, segregation with disease, tumor characteristics, mutation co-occurrence, and functional assay results (Easton D et al. Am J Hum Genet. 2007;81:873-883; Iversen ES Jr et al. Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1078-88; Lindor NM et al. Hum Mutat. 2012 Jan;33(1):8-21). Further, internal structural analysis suggests this alteration is likely pathogenic due to a highly increased global energy change as well as a higher local energy increase compared to other pathogenic variants within close proximity (Ambry Internal Data; Birrane G et al. Biochemistry, 2007 Jul;46:7706-12; Williams RS et al. Cell, 2009 Oct;139:87-99). Of note, this alteration is also referred to as 5236G>A in published literature. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
Gene |
RCV000256122 | SCV000321440 | pathogenic | not provided | 2020-11-10 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate a damaging effect: decreased transcription activation, abnormal protease sensitivity, binding specificity, and phosphopeptide binding, sensitivity to cisplatin, and absent ability to support growth in BRCA1-deficient mouse embryonic stem cells (Bouwman 2013, Thouvenot 2016, Woods 2016, Fernandes 2019); Multifactorial studies suggest this variant is associated with breast and ovarian cancer (Lindor 2012); Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in multiple individuals with breast and/or ovarian cancer, and segregated with disease in at least one family (Osorio 2002, Esteban-Cardenosa 2004, Ivevleva 2010); Also known as 5236G>A; This variant is associated with the following publications: (PMID: 17305420, 20727672, 15235020, 15172985, 26071757, 23867111, 30209399, 27272900, 30765603, 17924331, 26780556, 14684619, 17308087, 21447777, 11979449, 12955716, 10755399, 20516115, 21990134, 28781887, 29446198, 32318955, 32123317) |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000031219 | SCV000326159 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000219187 | SCV000699203 | pathogenic | Hereditary breast ovarian cancer syndrome | 2021-02-21 | criteria provided, single submitter | clinical testing | Variant summary: BRCA1 c.5117G>A (p.Gly1706Glu) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251342 control chromosomes. c.5117G>A has been widely reported in the literature in multiple individuals affected with Hereditary Breast And Ovarian Cancer Syndrome (example, Rebbeck_2018). These data indicate that the variant is very likely to be associated with disease. Several publications reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in loss of Homology Directed Repair (HDR) activity (example, Findlay_2018). Six clinical diagnostic laboratories, one consortium (CIMBA) and one expert panel (ENIGMA) have submitted clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic (n=4) to include the expert panel / likely pathogenic(n=4). Based on the evidence outlined above, the variant was classified as pathogenic. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000256122 | SCV000887714 | likely pathogenic | not provided | 2020-08-10 | criteria provided, single submitter | clinical testing | The best available variant frequency is uninformative because there are too few occurrences in population data. Found in at least one patient with expected phenotype for this gene. Predicted to have a damaging effect on the protein. Located in potentially critical domain of the protein. Assessment of experimental evidence suggests this variant results in abnormal protein function. |
Color Diagnostics, |
RCV000221607 | SCV000908991 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-07-20 | criteria provided, single submitter | clinical testing | This missense variant replaces glycine with glutamic acid at codon 1706 of the BRCA1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have reported that this variant impacts BRCA1 function in transcription activation assays (PMID: 17308087, 20516115, 27742776, 28781887), homology-directed repair assay (PMID: 23867111) and in a haploid cell proliferation assay (PMID: 30209399). This variant has been reported in at least nine individuals affected with breast and/or ovarian cancer (PMID: 11979449, 17262179, 20727672, 24240112, 25682074, 29928469) and as a recurrent mutation in the Spanish population (PMID: 23199084). This variant has been identified in 1/31406 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. |
CHEO Genetics Diagnostic Laboratory, |
RCV001170590 | SCV001333178 | pathogenic | Breast and/or ovarian cancer | 2019-04-09 | criteria provided, single submitter | clinical testing | |
Institute of Genomics, |
RCV000031219 | SCV001430695 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | criteria provided, single submitter | research | ||
Labcorp Genetics |
RCV000219187 | SCV001582576 | pathogenic | Hereditary breast ovarian cancer syndrome | 2023-12-18 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 1706 of the BRCA1 protein (p.Gly1706Glu). This variant is present in population databases (rs80356860, gnomAD 0.007%). This missense change has been observed in individual(s) with breast and/or ovarian cancer (PMID: 10755399, 11979449, 12385650, 20727672, 29446198). This variant is also known as 5236G>A. ClinVar contains an entry for this variant (Variation ID: 37638). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (PMID: 30209399) indicates that this missense variant is expected to disrupt BRCA1 function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects BRCA1 function (PMID: 20516115, 23867111, 28781887, 30209399). This variant disrupts the p.Gly1706 amino acid residue in BRCA1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 17262179, 22144684, 25948282, 27616075, 30209399, 30458859). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
All of Us Research Program, |
RCV000031219 | SCV004817589 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2023-12-11 | criteria provided, single submitter | clinical testing | This missense variant replaces glycine with glutamic acid at codon 1706 of the BRCA1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have reported that this variant impacts BRCA1 function in transcription activation assays (PMID: 17308087, 20516115, 27742776, 28781887), homology-directed repair assay (PMID: 23867111) and in a haploid cell proliferation assay (PMID: 30209399). This variant has been reported in at least nine individuals affected with breast and/or ovarian cancer (PMID: 11979449, 17262179, 20727672, 24240112, 25682074, 29928469) and as a recurrent mutation in the Spanish population (PMID: 23199084). This variant has been identified in 1/31406 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. |
Clinical Genetics Laboratory, |
RCV000256122 | SCV005199701 | pathogenic | not provided | 2022-05-27 | criteria provided, single submitter | clinical testing | |
Sharing Clinical Reports Project |
RCV000031219 | SCV000053819 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2011-02-16 | no assertion criteria provided | clinical testing | |
Breast Cancer Information Core |
RCV000031219 | SCV000145318 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 1 | 2002-05-29 | no assertion criteria provided | clinical testing | |
Brotman Baty Institute, |
RCV000031219 | SCV001243570 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro |